REDUCING THE IMPACT OF CHRONIC KIDNEY DISEASE (CKD): OPPORTUNITIES FOR RANDOMIZED CLINICAL TRIALS
- Discuss critical elements of the study design to optimize the conduct and impact of Phase III clinical trials in CKD.
- Identify interventions and therapies for CKD that are currently in clinical trials or are ready to be evaluated in clinical trials.
- Discuss mechanisms for pathways of cooperation among industry, academia, government, and patient advocacy groups for CKD trials.
For questions concerning program content, contact:
Dr. Michael Flessner, NIDDK, NIH
Dr. Yining Xie, NIDDK, NIH
For registration information, contact:
The Scientific Consulting Group, Inc.
656 Quince Orchard Road, Suite 210
Gaithersburg, MD 20878-1409
Tel: (301) 670-4990 x249
Fax: (301) 670-3815